The role of matrix metalloproteinases in pathogenesis, diagnostics, and treatment of human prostate cancer

Simple item record

Full item record

dc.contributor.authorWiśniowski, Tomasz
dc.contributor.authorBryda, Jarosław
dc.contributor.authorWątroba, Sławomir
dc.contributor.organizationDepartment of Urology and Urological Oncology, Cardinal Stefan Wyszynski Voivodship Specialist Hospital, Independent Public Healthcare Lublin, Polanden
dc.contributor.organizationDepartment of Veterinary Hygiene, Voivodship Veterinary Inspectorate, Lublin, Polanden
dc.contributor.organizationDepartment of Neonatology and Neonatal Intensive Care Unit, Independent Public Healthcare, Puławy, Polanden
dc.date.accessioned2024-03-14T08:25:59Z
dc.date.available2024-03-14T08:25:59Z
dc.date.issued2023
dc.description.abstractThe prostate gland is highly susceptible to oncogenic transformation, many times more than other sex tissues, such as seminal vesicles. In fact, prostate cancer (PCa) will be diagnosed in one in seven lifetime patients, making PCa the subject of intense research aimed at clarifying its biology and providing adequate treatment. PCa is the fourth most common cancer in the world in terms of the overall population and the second most common cancer for the male population. It is postulated that the development of PCa may be influenced by dietary factors, physical and sexual activity, androgens, obesity, and inflammation, but their role in the development of prostate cancer still remains unclear. Extracellular matrix metalloproteinases (MMPs) and tissue metalloproteinase inhibitors (TIMPs) play an important role in many physiological and pathological processes, including proliferation, migration, invasion, cell differentiation, participation in inflammatory processes and angiogenesis. Numerous studies point to a direct relationship between MMPs and both local tumor invasion and the formation of distant metastases. High activity of MMPs is observed in solid tumors of various origins, which positively correlates with a poor overall survival rate. Although biochemical diagnostic markers of PCa are currently available, from the point of view of clinical practice, it seems particularly important to develop new and more sensitive markers allowing for early diagnosis and long-term monitoring of patients after PCa treatment, and the assessment of MMP activity in urine and serum of patients are potential factors that could play such a role.en
dc.identifier.citationWiśniowski, Tomasz, Bryda, Jarosław and Wątroba, Sławomir. "The role of matrix metalloproteinases in pathogenesis, diagnostics, and treatment of human prostate cancer" Postępy Higieny i Medycyny Doświadczalnej, vol.77, no.1, 2023, pp.9-20. https://doi.org/10.2478/ahem-2023-0002en
dc.identifier.doi10.2478/ahem-2023-0002
dc.identifier.issn1732-2693
dc.identifier.urihttps://open.icm.edu.pl/handle/123456789/24016
dc.language.isoen
dc.publisherSciendoen
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Międzynarodowe*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectextracellular matrixen
dc.subjectprostate-specific antigenen
dc.subjectprostatic hyperplasiaen
dc.subjectmatrix metalloproteinasesen
dc.subjectprostatic neoplasmsen
dc.titleThe role of matrix metalloproteinases in pathogenesis, diagnostics, and treatment of human prostate canceren
dc.typearticleen
Files for this record
Original bundle
Now showing 1 - 1 of 1
Name: The-role-of-matrix-metalloproteinases-in-pathogenesis-diagnostics-and-treatment-of-human-prostate-cancer.pdf
Size: 1.37 MB
Format: Adobe Portable Document Format
Description:
Download
License files
Name: license.txt
Size: 491 B
Format: Plain Text
Description:
Download
Belongs to collection
Artykuły / Articles